Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2020 1
2021 1
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Fusion-negative rhabdomyosarcoma 3D organoids to predict effective drug combinations: A proof-of-concept on cell death inducers.
Savary C, Luciana L, Huchedé P, Tourbez A, Coquet C, Broustal M, Lopez Gonzalez A, Deligne C, Diot T, Naret O, Costa M, Meynard N, Barbet V, Müller K, Tonon L, Gadot N, Degletagne C, Attignon V, Léon S, Vanbelle C, Bomane A, Rochet I, Mournetas V, Oliveira L, Rinaudo P, Bergeron C, Dutour A, Cordier-Bussat M, Roch A, Brandenberg N, El Zein S, Watson S, Orbach D, Delattre O, Dijoud F, Corradini N, Picard C, Maucort-Boulch D, Le Grand M, Pasquier E, Blay JY, Castets M, Broutier L. Savary C, et al. Cell Rep Med. 2023 Dec 19;4(12):101339. doi: 10.1016/j.xcrm.2023.101339. Cell Rep Med. 2023. PMID: 38118405 Free PMC article.
Loss of Chromosome 3q Is a Prognostic Marker in Fusion-Negative Rhabdomyosarcoma.
Dehner CA, Bell RC, Cao Y, He K, Chrisinger JSA, Armstrong AE, Yohe M, Shern J, Hirbe AC. Dehner CA, et al. JCO Precis Oncol. 2023 Sep;7:e2300037. doi: 10.1200/PO.23.00037. JCO Precis Oncol. 2023. PMID: 37738543 Free PMC article.
Copy number variation (CNV) data from the National Cancer Institute were analyzed to assess for prognostically significant CNV aberrations in FOXO1 fusion-negative (FN)- versus fusion-positive (FP)-RMS. ...RESULTS: Chr8 gain is a highly prevalent CNV in embryonal RMS and s …
Copy number variation (CNV) data from the National Cancer Institute were analyzed to assess for prognostically significant CNV aberra …
Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Abbou S, Klega K, Tsuji J, Tanhaemami M, Hall D, Barkauskas DA, Krailo MD, Cibulskis C, Nag A, Thorner AR, Pollock S, Imamovic-Tuco A, Shern JF, DuBois SG, Venkatramani R, Hawkins DS, Crompton BD. Abbou S, et al. J Clin Oncol. 2023 May 1;41(13):2382-2393. doi: 10.1200/JCO.22.00409. Epub 2023 Feb 1. J Clin Oncol. 2023. PMID: 36724417
However, the use of Rhabdo-Seq in FN-RMS samples also identified single-nucleotide variants, such as MYOD1(L122R), previously associated with prognosis. Identification of pathognomonic translocations between PAX3 or PAX7 and FOXO1 by Rhabdo-Seq was the best method for meas …
However, the use of Rhabdo-Seq in FN-RMS samples also identified single-nucleotide variants, such as MYOD1(L122R), previously associated wit …
Immunohistochemical detection of PAX-FOXO1 fusion proteins in alveolar rhabdomyosarcoma using breakpoint specific monoclonal antibodies.
Azorsa DO, Bode PK, Wachtel M, Cheuk ATC, Meltzer PS, Vokuhl C, Camenisch U, Khov HL, Bode B, Schäfer BW, Khan J. Azorsa DO, et al. Mod Pathol. 2021 Apr;34(4):748-757. doi: 10.1038/s41379-020-00719-0. Epub 2020 Dec 9. Mod Pathol. 2021. PMID: 33299109 Free PMC article.
Since patients with fusion-positive ARMS (FP-RMS) have a poor prognosis and are treated with an aggressive therapeutic regimen, correct classification is of clinical importance. ...Subsequently, we stained 26 primary tumor sections and a rhabdomyosarcoma tissue array and d …
Since patients with fusion-positive ARMS (FP-RMS) have a poor prognosis and are treated with an aggressive therapeutic regimen, corre …
Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusion-negative rhabdomyosarcoma: A report from the Children's Oncology Group.
Teot LA, Schneider M, Thorner AR, Tian J, Chi YY, Ducar M, Lin L, Wlodarski M, Grier HE, Fletcher CDM, van Hummelen P, Skapek SX, Hawkins DS, Wagers AJ, Rodriguez-Galindo C, Hettmer S. Teot LA, et al. Cancer. 2018 May 1;124(9):1973-1981. doi: 10.1002/cncr.31286. Epub 2018 Feb 20. Cancer. 2018. PMID: 29461635 Free PMC article.
ERK phosphorylation is dependent on cell adhesion in a subset of pediatric sarcoma cell lines.
Yoon HY, Maron BY, Girald-Berlingeri S, Gasilina A, Gollin JC, Jian X, Akpan I, Yohe ME, Randazzo PA, Chen PW. Yoon HY, et al. Biochim Biophys Acta Mol Cell Res. 2022 Aug;1869(8):119264. doi: 10.1016/j.bbamcr.2022.119264. Epub 2022 Apr 3. Biochim Biophys Acta Mol Cell Res. 2022. PMID: 35381293 Free article.
Osteosarcoma (OS) and Pax-Foxo1 fusion negative rhabdomyosarcoma (FN-RMS) are pediatric sarcomas with poor prognoses in patients with advanced disease. In both malignancies, an actin binding protein has been linked to poor prognosis. ...
Osteosarcoma (OS) and Pax-Foxo1 fusion negative rhabdomyosarcoma (FN-RMS) are pediatric sarcomas with poor prognoses in patients with …
Germline Genetic Testing and Survival Outcomes Among Children With Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Martin-Giacalone BA, Li H, Scheurer ME, Casey DL, Dugan-Perez S, Marquez-Do DA, Muzny D, Gibbs RA, Barkauskas DA, Hall D, Stewart DR, Schiffman JD, McEvoy MT, Khan J, Malkin D, Linardic CM, Crompton BD, Shern JF, Skapek SX, Venkatramani R, Hawkins DS, Sabo A, Plon SE, Lupo PJ. Martin-Giacalone BA, et al. JAMA Netw Open. 2024 Mar 4;7(3):e244170. doi: 10.1001/jamanetworkopen.2024.4170. JAMA Netw Open. 2024. PMID: 38546643 Free PMC article.
These findings suggest that germline CPV testing may aid in clinical prognosis and should be considered in prospective risk-based clinical trials....
These findings suggest that germline CPV testing may aid in clinical prognosis and should be considered in prospective risk-based cli …